Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan

Wakiguchi, Hiroyuki; Kaneko, Utako; Sato, Satoshi; Imagawa, Tomoyuki; Narazaki, Hidehiko; Miyamae, Takako

doi:10.3390/v15051205

Cited by 6 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 95% of the infected patients had mild symptoms ( 12 ) and the impact of COVID-19 on patients’ relapse, immune parameters and treatment was not analyzed. Another study analyzed clinical features of COVID-19 in pediatric rheumatic disease, of which 5 patients had TAK ( 13 ). Unfortunately, their features and outcomes were not analyzed separately.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort

Kong,

Wang,

Fan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesTo investigate the characteristics of COVID-19 and its impact on patients with Takayasu’s arteritis (TAK).MethodsA web-based survey was administered to a TAK cohort and their co-residents in China during January 2023. Infection symptoms, post-acute sequelae of COVID-19 (PASC), potential impacts of COVID-19 on patients’ disease condition, treatment and immune-related parameters were analyzed. In addition, risk factors for COVID-19 and disease relapse after infection were explored.ResultsThe infection rate was significantly lower in patients with TAK than in co-residents (79.13% vs 90.67%, p=0.025). TAK patients were more prone to gastrointestinal symptoms (17.78% vs 5.88%, p=0.024), sleep problems (25.15% vs 10.29%, p=0.011), and symptoms involving more than 2 organs (58.90% vs 35.29%, p=0.001) after infection. Although only 2.45% of TAK patients were hospitalized and none progressed to life-threatening conditions, they were more likely to suffer from PASC (26.38% vs 13.24%, p=0.029), especially active patients. Active disease after the pandemic was significantly lower in infected patients than uninfected patients (21/163, 12.88% vs. 11/43, 25.58%, p=0.041). The presence of multiple system symptoms was a risk factor for active TAK after infection [OR: 3.62 (95% CI 1.06-12.31), p=0.040]. Moreover, csDMARDs treatment was a risk factor for COVID-19 infection [OR: 3.68 (95% CI 1.56-8.66), p=0.002].ConclusionAlthough TAK patients with COVID-19 have more acute and post-acute symptoms, there is no adverse outcome and the risk of disease relapse does not increase. Patients treated with csDMARDs may be at higher risk of infection and deserve more clinical attention.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort

Kong,

Wang,

Fan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Verlauf der COVID-19-Pandemie bei pädiatrisch-rheumatologischen Patienten in Deutschland über die ersten 3 Jahre (2020 bis 2022)

Klein,

Huppertz,

Horneff

2024

Z Rheumatol

View full text Add to dashboard Cite

Clinical characteristics and outcomes of COVID-19 in pediatric patients with rheumatic diseases

Wang,

Su,

et al. 2024

Pediatr Res

View full text Add to dashboard Cite

Background This study investigates the clinical characteristics and outcomes of pediatric patients with rheumatic diseases infected with COVID-19 in China. Methods We conducted a retrospective analysis of pediatric patients with rheumatic diseases who contracted COVID-19. Data were collected via a comprehensive questionnaire with a 14-day follow-up. Multivariable logistic regression was used to assess severe outcomes, and network analyses evaluated symptom correlations. Results A total of 1070 cases were collected. Fever (88.05%) and cough (62.75%) were the most common symptoms. Cough, nasal congestion, and runny nose exhibited a stronger correlation with each other. A higher incidence of fever reduced the incidence of two single symptoms (nasal congestion [r = −0.833], runny nose [r = −0.762]). Vaccinated children showed a shorter time to negative COVID-19 conversion (7.21 days vs. 7.63 days, p < 0.05) and lower hospitalization rates (p = 0.025). Prolonged symptom duration was associated with older age (OR: 1.07 [1.04–1.11]; p < 0.001) and systemic lupus erythematosus (OR: 1.47 [1.01–2.12]; p = 0.046). Conclusions Pediatric patients with rheumatic diseases exhibited a wide range of clinical symptoms after COVID-19 infection. The infection generally did not lead to severe outcomes in this study. COVID-19 vaccination was associated with reduced hospitalization risk and expediting the time to negativity for virus. Impacts This manuscript demonstrates a comprehensive analysis of the clinical characteristics and outcomes of COVID-19 infection in pediatric patients with rheumatic diseases in China. It provides critical insights into the specific challenges faced by this vulnerable population and offers practical recommendations for improving patient management during periods of increased infectious risk.

show abstract

Clinical Features of COVID-19 in Pediatric Rheumatic Diseases: 2020–2022 Survey of the Pediatric Rheumatology Association of Japan

Cited by 6 publications

References 31 publications

COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort

COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort

Verlauf der COVID-19-Pandemie bei pädiatrisch-rheumatologischen Patienten in Deutschland über die ersten 3 Jahre (2020 bis 2022)

Clinical characteristics and outcomes of COVID-19 in pediatric patients with rheumatic diseases

Contact Info

Product

Resources

About